Skip to main content
. 2020 Dec 18;12(12):3821. doi: 10.3390/cancers12123821

Figure 2.

Figure 2

Loss of GRP78 alters the actions of IGFBP-3 on breast cancer cells. (A,i) The percentage cell death was assessed by trypan blue dye exclusion method in Hs578T cells treated with IGFBP-3 in combination with an apoptotic dose of C2 in the presence or absence of target siRNA to GRP78 or nonsilencing siRNA. Effective GRP78 silencing is shown in (A,ii). (B,i) Cell invasion was measured using the transwell invasion assay with crystal violet staining in Hs578T cells treated with IGFBP-3 with and without GRP78 knocked-down (×20). (B,ii) Quantification of stained invaded cells using a microplate reader. Effective GRP78 silencing is shown in (B,iii). (C,i) Representative Western immunoblot indicating effective silencing of GRP78 using siRNA (ON-TARGET plus Human HSPA5 (3309) siRNA-SMARTPOOL) (C,ii) Cell invasion was measured using the transwell invasion assay with crystal violet staining in MDA-MB-231 cells treated with IGFBP-3 with and without GRP78 knocked-down (×20). (C,iii) Quantification of stained invaded cells using a microplate reader. Effective GRP78 silencing is shown in (C,iv). The whole blots (uncropped blots) are shown in the Supplemental Materials.